David Green, the president of Harvard Bioscience, takes it personally when the company’s stock price takes a swan dive, like it did in May after the company announced disappointing first-quarter results.

He said that plunge cost him $10 million.

But, tell him that loss is only on paper, and the look you get will convince you of the pain he has incurred.

Green and Chane Graiziano acquired HBIO in 1996 and took it public in 2000, and today still hold some 18 percent of company stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.